Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Common Equity: 2010-2025

Historic Common Equity for China Pharma Holdings (CPHI) over the last 15 years, with Sep 2025 value amounting to $8.3 million.

  • China Pharma Holdings' Common Equity rose 27.35% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 27.35%. This contributed to the annual value of $7.7 million for FY2024, which is 3.93% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Common Equity is $8.3 million, which was up 28.66% from $6.5 million recorded in Q2 2025.
  • China Pharma Holdings' 5-year Common Equity high stood at $8.3 million for Q3 2025, and its period low was $2.8 million during Q3 2022.
  • For the 3-year period, China Pharma Holdings' Common Equity averaged around $6.8 million, with its median value being $7.0 million (2025).
  • As far as peak fluctuations go, China Pharma Holdings' Common Equity tumbled by 58.64% in 2022, and later soared by 115.56% in 2023.
  • China Pharma Holdings' Common Equity (Quarterly) stood at $6.0 million in 2021, then fell by 28.71% to $4.3 million in 2022, then spiked by 73.77% to $7.5 million in 2023, then increased by 3.93% to $7.7 million in 2024, then rose by 27.35% to $8.3 million in 2025.
  • Its Common Equity was $8.3 million in Q3 2025, compared to $6.5 million in Q2 2025 and $7.0 million in Q1 2025.